Trained in immunology and international business, Lundstrom has over 30 years of experience with a focus on antibody therapeutics, according to a company statement.
"With the addition of Mr Lundstrom, ImmunoPrecise further strengthens its strategic and operational commitment to industry-leading therapeutic antibody discovery for both its clients and the company's emerging internal pipeline," said Chairman Dr James Kuo.
READ: ImmunoPrecise Antibodies adds biotechnology executive Dr Stefan Lang as chief business officer
Lundstrom started his career with product and clinical development for Novo Nordisk in Europe in 1987 and moved to the US in 1993 to form a dedicated business development function.
He subsequently served as business development and financing lead for companies such as OGS (now UCB), SangStat (now a division of Sanofi Genzyme), ACADIA and ISCO. This included SangStat's $600 million sale and integration into Genzyme in 2003.
Since 2011, Lundstrom has established global business leadership in transgenic animals for the discovery of human therapeutic antibodies, first with OMT, and then with Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) after its $178 million acquisition of OMT.
"We welcome Brian Lundstrom to our board and consider his immense experience in developing and closing pharma partnerships as a tremendous benefit to the company, as ImmunoPrecise continues to take the stage as a leader in data-driven, therapeutic antibody discovery," said CEO Dr Jennifer Bath.
ImmunoPrecise, based in Victoria, British Columbia, is a full-service antibody discovery company. Its goal is to deliver its clients therapeutically significant custom antibodies that have the greatest probability of ultimately succeeding in clinical trials.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham